000			01479 a2200397 4500
005			20250515081114.0
264		0	_c20080221
008			200802s 0 0 eng d
022			_a0960-9776
024	7		_a10.1016/j.breast.2007.07.016 _2doi
040			_aNLM _beng _cNLM
100	1		_aRegan, Meredith M
245	0	0	_aUsing clinical trial data to tailor adjuvant treatments for individual patients. _h[electronic resource]
260			_bBreast (Edinburgh, Scotland) _cDec 2007
300			_aS98-104 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650	0	4	_aAntibodies, Monoclonal _xpharmacology
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAntineoplastic Agents _xpharmacology
650	0	4	_aBreast Neoplasms _xdrug therapy
650	0	4	_aChemotherapy, Adjuvant
650	0	4	_aClinical Trials as Topic
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aNeoplasm Staging
650	0	4	_aRadiotherapy, Adjuvant
650	0	4	_aReceptor, ErbB-2 _xdrug effects
650	0	4	_aReceptors, Estrogen _xdrug effects
650	0	4	_aReceptors, Progesterone
650	0	4	_aSurvival Analysis
650	0	4	_aTrastuzumab
650	0	4	_aTreatment Outcome
700	1		_aGelber, Richard D
773	0		_tBreast (Edinburgh, Scotland) _gvol. 16 Suppl 2 _gp. S98-104
856	4	0	_uhttps://doi.org/10.1016/j.breast.2007.07.016 _zAvailable from publisher's website
999			_c17249601 _d17249601